A Japan-South Korea joint research project on intraductal papillary tumour, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma

A Japan-South Korea joint research project on intraductal papillary tumour, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma - A Japan-South Korea joint research project on intraductal papillary tumour, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022933

Enrollment

400

Registered

2016-09-30

Start date

2016-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intraductal papillary neoplasm of the bile duct, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases of intraductal papillary neoplasm of the bile duct, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma in Japan and South Korea

Exclusion criteria

Exclusion criteria: Non-consent of the patient

Design outcomes

Primary

Measure	Time frame
Cases of intraductal papillary neoplasm of the bile duct, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma are coded so that individual patients cannot be identified and personal information is protected. Subsequently, data are registered into a large-scale Japan-South Korea joint database. Details of the registered data are described below. [Registered data] Name of the hospital, preoperative diagnosis, sex, age, height, weight, presence or absence of smoking, presence or absence of drinking, biochemical laboratory findings (CEA, CA19-9, DUPAN-2, WBC, RBC, Plt, Hb, ALT, AST, LDH, ganma-GTP, ALP, T-bil, D-bil, CRP, TG, and Tcho), detailed pathological findings regarding the intraductal papillary neoplasm of the bile duct, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma (localization of the cystic lesions, maximum diameter, and presence of any communication between the cysts and the bile duct), date of surgery, operative procedure, pathological findings (lymph node metastasis, portal vein invasion, hepatic vein invasion, hepatic artery invasion, bile duct invasion, and liver and duodenum bile duct stump findings) relapse date, final diagnosis date, date and time of death, etc. An Excel file with the above data is sent, and responses are entered using a pull-down list. Once responses are completed, the file is returned, and data are analysed. Haematoxylin and eosin-stained and immune-stained thin sections are prepared and submitted, so that pathological specimens can be examined by two pathologists (N.Y.,F.T.and T.F.)	—

Measure

Time frame

Cases of intraductal papillary neoplasm of the bile duct, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma are coded so that individual patients cannot be identified and personal information is protected. Subsequently, data are registered into a large-scale Japan-South Korea joint database. Details of the registered data are described below. [Registered data] Name of the hospital, preoperative diagnosis, sex, age, height, weight, presence or absence of smoking, presence or absence of drinking, biochemical laboratory findings (CEA, CA19-9, DUPAN-2, WBC, RBC, Plt, Hb, ALT, AST, LDH, ganma-GTP, ALP, T-bil, D-bil, CRP, TG, and Tcho), detailed pathological findings regarding the intraductal papillary neoplasm of the bile duct, mucinous cystic tumour or neoplasm, and papillary bile duct carcinoma (localization of the cystic lesions, maximum diameter, and presence of any communication between the cysts and the bile duct), date of surgery, operative procedure, pathological findings (lymph node metastasis, portal vein invasion, hepatic vein invasion, hepatic artery invasion, bile duct invasion, and liver and duodenum bile duct stump findings) relapse date, final diagnosis date, date and time of death, etc. An Excel file with the above data is sent, and responses are entered using a pull-down list. Once responses are completed, the file is returned, and data are analysed. Haematoxylin and eosin-stained and immune-stained thin sections are prepared and submitted, so that pathological specimens can be examined by two pathologists (N.Y.,F.T.and T.F.)

—

Countries

Japan,Asia(except Japan)

Contacts

Public Contactkeiichi Kubota

Dokkyo Medical University Second Department of Surgery

kubotak@dokkyomed.ac.jp0282-87-2158

Outcome results